A PHASE 1/2 DOSE ESCALATION AND COMBINATION COHORT STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF BMS-986226 (ANTI-ICOS MAB) ALONE OR IN COMBINATION WITH NIVOLUMAB OR IPILIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
2017-000238-73TUMORES SÓLIDOS AVANZADOSFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR
